Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 37 - Drugs for immunological or allergic disorders
Patents for A61P 37 - Drugs for immunological or allergic disorders (117,141)
08/2003
08/21/2003WO2003068242A1 Phospholipids as caspase inhibitor prodrugs
08/21/2003WO2003068237A1 Beta-sheet mimetics and composition and methods relating thereto
08/21/2003WO2003068235A1 Nicotinamide derivatives useful as pde4 inhibitors
08/21/2003WO2003068234A1 Nicotinamide derivatives and a tiotropium salt in combination for the treatment of e.g. inflammatory, allergic and respiratory diseases
08/21/2003WO2003068232A1 Nicotinamide derivatives useful as pde4 inhibitors
08/21/2003WO2003068230A1 Substituted pyridinones as modulators of p38 map kinase
08/21/2003WO2003068228A1 Aryl ureas with angiogenesis inhibiting activity
08/21/2003WO2003068225A1 Microglia inhibitors for interrupting immune reactions induced by interleukin 12 and ifn$g(g)
08/21/2003WO2003068201A2 High affinity antibody having a tcr-like specificity and use in detection and treatment
08/21/2003WO2003068197A1 Method for systemic drug delivery through the nail
08/21/2003WO2003068171A2 Method and composition for treatment of inflammation and aids-associated neurological disorders
08/21/2003WO2003068169A2 Stabilized synthetic immunogen delivery system
08/21/2003WO2003068146A2 Identification of actinobacillus actinomycetemcomitans antigens for use in the diagnosis, treatment, and monitoring of periodontal diseases
08/21/2003WO2003068140A2 Novel pyridazine derivatives, use of the same as medicaments, pharmaceutical compositions and method for producing the same
08/21/2003WO2003067991A1 Compositions and methods for treatment of microbial infections
08/21/2003WO2003060142A9 Compositions and methods for controlled release
08/21/2003WO2003055913A3 Secreted protein
08/21/2003WO2003045906A3 Synthesis of 2-cyanoziridine-1-carboxamide
08/21/2003WO2003039479A3 Polymeric thiol-linked prodrugs
08/21/2003WO2003027075A3 Substituted pyrazolyl benzenesulfamide compounds for the treatment of inflammation
08/21/2003WO2003024474A3 Anti-inflammatory agent
08/21/2003WO2003024404A3 Chemokines as adjuvants of immune response
08/21/2003WO2003020751A3 Homing peptides
08/21/2003WO2003018052A8 Moraxella (branhamella) catarrhalis polypeptides and corresponding dna fragments
08/21/2003WO2003007930A3 Use of sulfonyl aryl or heteroaryl hydroxamic acids and derivatives thereof as aggrecanase inhibitors
08/21/2003WO2002098459A3 USE OF IgM ANTIBODIES AGAINST dsDNA IN SYSTEMIC LUPUS ERYTHEMATOSUS WITH NEPHRITIS
08/21/2003WO2002092620A3 Peptides and related molecules that bind to tall-1
08/21/2003WO2002088664A3 Control of compactability through crystallization
08/21/2003WO2002085311A3 Hcg formulation
08/21/2003WO2002067861A3 Oncolytic adenoviral vectors
08/21/2003WO2002066045A3 Methods for modulating an immune response by modulating the interaction between ctla4 and pp2a
08/21/2003WO2002064748A3 Multipotent adult stem cells, sources thereof, methods of obtaining and maintaining same, methods of differentiation thereof, methods of use thereof and cells derived thereof
08/21/2003WO2002062999A3 Proteins and nucleic acids encoding same
08/21/2003WO2002057452A3 Human proteins, polynucleotides encoding them and methods of using the same
08/21/2003WO2002044209A3 Cytonkine receptor zcytor19
08/21/2003WO2002036611A3 Immunomodulatory peptides derived from heat shock proteins and uses thereof
08/21/2003WO2002036573A3 8- substituted-2, 6-methano-3-benzazocines and 3-substituted morphinanes as opioid receptor binding agents
08/21/2003WO2002020722A9 Methods and compositions for in vitro targeting
08/21/2003WO2002020047A9 Chlamydial peptides and their mimics in demyelinating disease
08/21/2003WO2001092581A3 Compositions and methods for the therapy and diagnosis of ovarian cancer
08/21/2003WO2001090342A3 Genetic engineering of vascular grafts to resist disease
08/21/2003WO2001085792A3 Mu-1, member of the cytokine receptor family
08/21/2003US20030159163 Transgenic animal; animal models; gene expression; skin disorders
08/21/2003US20030158413 A thiochromane-7-carboxamide derivatives as Rho kinase enzyme inhibitor; nontoxic, anticancer agents
08/21/2003US20030158409 Pyridine derivatives inhibiting angiogenesis and/or vegf receptor tyrosine kinase
08/21/2003US20030158406 Enzyme inhibitor treating autoimmune diseases, Alzheimer's disease, atherosclerosis
08/21/2003US20030158399 Compositions and methods for the treatment and diagnosis of immune disorders
08/21/2003US20030158390 Protein; Escherichia culture product; genetic engineering; fusion
08/21/2003US20030158388 MAGE-10 encoding cDNA, the tumor rejection antigen precursor MAGE-10, antibodies specific to the molecule, and uses thereof
08/21/2003US20030158381 Novel insulin/igf/relaxin family polypeptides and dnas thereof
08/21/2003US20030158266 Particularly septic shock
08/21/2003US20030158246 For the treatment of prostaglandin mediated diseases, such as allergic asthma or rhinitis.
08/21/2003US20030158242 Salt with a sugar substitute, especially saccharin, cyclamate or acesulfame.
08/21/2003US20030158238 Treating diseases such as cancer, inflammatory disorders, restenosis,
08/21/2003US20030158225 Novel compounds
08/21/2003US20030158219 N-substituted spiropiperidine compounds as ligands for ORL-1 receptor
08/21/2003US20030158204 Diamino phenothiazine derivatives and composition comprising same
08/21/2003US20030158192 Activating cytokine biosynthesis, viricides treating a viral disease, antitumor agents, immunomodulators
08/21/2003US20030158189 Non-steroidal antiinflammatory agents treating bone disorders, Crohn's disease, and inflammatory bowel disease, respiratory disorders such as chronic obstructive pulmonary disease, infections, autoimmune diseases
08/21/2003US20030158187 Genetic polymorphisms in the preprotachy kinin gene
08/21/2003US20030158176 Quaternary ammonium compounds
08/21/2003US20030158159 Administering a calcitonin-like agent and a dehydroepiandrosterone-like agent to treat an indivisual for bone density loss
08/21/2003US20030158138 Nucleic acid construct encoding a processing component derived from the N-terminal region of the hepatitis virus ORF2, and an antigenic polypeptide
08/21/2003US20030158136 Materials and methods relating to immune responses to fusion proteins
08/21/2003US20030158125 Polysaccharidic esters of n-derivatives of glutamic acid
08/21/2003US20030158099 Cancer therapy
08/21/2003US20030158086 For use in therapy ofweak immunity and immunodeficiencies, hormonal disorders, as a nutrient for skin, hair, nails, in food supplements, cosmetics
08/21/2003US20030157502 Induce apoptosis; antitumor, anticancer agents
08/21/2003US20030157479 Antigen arrays for treatment of allergic eosinophilic diseases
08/21/2003US20030157204 A plant extracts as immunomodulator treating autoimmune disorders, antiallergens treating hypersensitivity reactions; used as pharmaceuticals, cosmetics or dietary supplements
08/21/2003US20030157160 Vaccine for modulating between T1 and T2 immune responses
08/21/2003US20030157138 Pharmaceutical or cosmetic carrier or composition for topical application onto skin and/or mucosal membranes; treatment of skin diseases or disorders including eczema, psoriasis and dermatitis
08/21/2003US20030157135 Enhancement and/or extension of antigen-specific Th1-type responses, in particular, CD8+ T cell responses; for treatment of various infectious and neoplastic diseases
08/21/2003US20030157128 Comprises exogenous nucleotide sequences which encode exogenous amino acid sequences; infection of host cell with recombinant Yellow Fever Virus provides for expression of exogenous nucleic acid and production of antigen
08/21/2003US20030157108 80-100% of the glycoprotein has a mature core carbohydrate structure which lacks fucose, attached to a Fc region
08/21/2003US20030157102 Administering a ligand having a population of activated t cells and binding specificity for the extracellular domain of CD28 to enhance t cell proliferation and increase overall lymphokine levels
08/21/2003US20030157096 Used to antagonize the effects of T-cell inducible factor in certain diseases
08/21/2003US20030157094 Prevention, therapy liver disorders, inflammatory bowel diseases, Crohn's disease; antiulcer agents; rheumatic diseases
08/21/2003US20030157090 Redox systems; accumulation of polypeptide in plant cell; genetic engineering
08/21/2003US20030157084 Methods for preparing purified prostaglandin E synthase
08/21/2003US20030157073 Methods for pretreating a subject with apoptotic cells
08/21/2003US20030157059 Vaccine; infection therapy
08/21/2003US20030157054 Recombinant tumor specific antibody and use thereof
08/21/2003CA2513198A1 Microorganism for genetic therapeutic treatment of proliferative diseases
08/21/2003CA2476556A1 Modulation of immune response by non-peptide binding stress response polypeptides
08/21/2003CA2476553A1 Embryonic-like stem cells derived from post-partum mammalian placenta and uses and methods of treatment using said cells
08/21/2003CA2476239A1 A nucleic acid encoding a g-protein-coupled receptor, and uses thereof
08/21/2003CA2476126A1 Shark cartilage extracts and use thereof for immunomodulation
08/21/2003CA2476113A1 Beta-sheet mimetics and composition and methods relating thereto
08/21/2003CA2475838A1 Cytotoxic t-cell epitopes from chlamydia
08/21/2003CA2475770A1 Microglia inhibitors for interrupting immune reactions induced by interleukin 12 and ifn.gamma.g(g)
08/21/2003CA2475708A1 Nicotinamide derivatives useful as pde4 inhibitors
08/21/2003CA2475703A1 Aryl ureas with angiogenesis inhibiting activity
08/21/2003CA2475439A1 Novel pyridazine derivatives, use of the same as medicaments, pharmaceutical compositions and method for producing the same
08/21/2003CA2475102A1 Stabilized synthetic immunogen delivery systems
08/21/2003CA2474885A1 Mutated gene coding for a lat protein and the biological applications thereof
08/21/2003CA2474782A1 Antibody having a t-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease
08/21/2003CA2474405A1 Medicament for the treatment of choroidal neovascularisation
08/21/2003CA2472822A1 Chemical compounds
08/21/2003CA2471392A1 Method for the generation of genetically modified vertebrate precursor lymphocytes and use thereof for the production of heterologous binding proteins
1 ... 694 695 696 697 698 699 700 701 702 703 704 705 706 707 708 709 710 711 712 713 714 ... 1172